Rigel PharmaceuticalsRIGL
Price$46.97

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $276.8M+54.4% YoYTTM through 30 Jun 2026
Net Income $321.9M+1,741.1% YoYTTM through 30 Jun 2026
Free Cash Flow $79.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin92.2%
EBITDA Margin32.4%
Operating Margin20.2%
Net Margin116.3%

Returns

91.1%ROE
61.8%ROA
42.3%ROIC

Balance Sheet Health

Debt / Equity0.11x
Current Ratio2.62x
Net Debt-$101.7Mnet cash position
Cash & Equivalents$60.8M

Quality Metrics

Altman Z-Score4.28
Piotroski F-Score5 / 9
FCF Margin28.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $294.3M
Diluted EPS$16.89TTM
'19'20'21'22'23'24'25
FY2025: $19.48

Dividend

No dividend

Capital Allocation

R&D Spend$43.7M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.